Coloma Jason V 4
4 · Maze Therapeutics, Inc. · Filed Jun 3, 2026
Research Summary
AI-generated summary of this filing
Maze Therapeutics (MAZE) CEO Jason Coloma Sells Shares
What Happened
Jason V. Coloma, CEO of Maze Therapeutics (MAZE), sold a total of 6,643 shares on June 1, 2026 in two open-market/private-sale transactions, generating proceeds of approximately $174,048. The filings report 6,090 shares at $26.20 (≈ $159,537) and 553 shares at $26.24 (≈ $14,511). These sales were effected pursuant to a Rule 10b5-1 trading plan.
Key Details
- Transaction date: June 1, 2026 (Form 4 filed June 3, 2026) — filing appears timely.
- Transaction type: Sale (Code S) — open market or private sale.
- Share amounts & reported prices: 6,090 @ $26.20; 553 @ $26.24; total 6,643 shares for ≈ $174,048.
- Price details: Filings note weighted-average pricing and multiple executions with prices in ranges reported ($26.00–$26.545 and $26.00–$26.50); the filer can provide a full breakdown on request (see footnotes).
- Holdings: The filing does not state the reporter’s total MAZE shares owned after these transactions.
- Ownership/beneficial interest: Some of the securities are held directly by the Coloma Family Trust and The Coloma 2021 Irrevocable Trust, for which Mr. Coloma and his spouse serve as co-trustees.
- Plan: Transactions were made under a 10b5-1 trading plan adopted Feb 6, 2026 (footnote).
- Timeliness: No late filing flag reported.
Context
These are sales (not purchases), commonly used for liquidity or portfolio management; the presence of a 10b5-1 plan indicates the trades were pre-authorized and executed according to that plan. The trusts named as holders mean the reported sales relate to trust-held shares rather than directly to a personal brokerage account. No inference should be drawn about the company’s prospects from routine, plan-driven insider sales.
Insider Transaction Report
- Sale
Common Stock
[F1][F2][F3]2026-06-01$26.20/sh−6,090$159,537→ 344,897 total(indirect: By Trust) - Sale
Common Stock
[F1][F4][F5]2026-06-01$26.24/sh−553$14,511→ 27,970 total(indirect: By Trust)
Footnotes (5)
- [F1]This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 6, 2026.
- [F2]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.00 to $26.545 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 4 of this Form 4.
- [F3]These securities are directly held by the Coloma Family Trust (the "Family Trust"), for which the reporting person and his spouse serve as co-trustees.
- [F4]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.00 to $26.50 per share, inclusive.
- [F5]These securities are directly held by The Coloma 2021 Irrevocable Trust (the "Irrevocable Trust"), for which the reporting person and his spouse serve as co-trustees.